Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
239.20
+2.09 (0.88%)
Nov 20, 2024, 4:00 PM EST - Market closed
Penumbra Revenue
Penumbra had revenue of $301.04M in the quarter ending September 30, 2024, with 11.11% growth. This brings the company's revenue in the last twelve months to $1.16B, up 16.96% year-over-year. In the year 2023, Penumbra had annual revenue of $1.06B with 24.95% growth.
Revenue (ttm)
$1.16B
Revenue Growth
+16.96%
P/S Ratio
7.95
Revenue / Employee
$277,090
Employees
4,200
Market Cap
9.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
Dec 31, 2019 | 547.41M | 102.47M | 23.03% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Henry Schein | 12.50B |
Charles River Laboratories International | 4.06B |
Teleflex | 3.03B |
Exact Sciences | 2.69B |
Bio-Rad Laboratories | 2.58B |
Qiagen | 1.97B |
HealthEquity | 1.10B |
Intra-Cellular Therapies | 613.73M |
PEN News
- 16 hours ago - Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference - PRNewsWire
- 16 days ago - New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options - PRNewsWire
- 21 days ago - Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Penumbra, Inc. Reports Third Quarter 2024 Financial Results - PRNewsWire
- 5 weeks ago - Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke - PRNewsWire
- 7 weeks ago - Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024 - PRNewsWire
- 2 months ago - Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe - PRNewsWire
- 3 months ago - Penumbra, Inc. to Present at the Baird Global Healthcare Conference - PRNewsWire